Currently, there is one ongoing clinical trial assessing the efficacy of cediranib in combination with selumetinib sulfate (AZD6244), a MEK inhibitor, in the treatment of solid malignancies, including metastatic melanoma (NCT01364051). The gene discussed is MAP2K7; the disease is metastatic melanoma.